Oral cancer patients with less circulating tumour cells live longer than those with more: Study

Published on Mar 27, 2022 12:27 PM IST

The study was published in the international peer-reviewed Journal Triple OOO. It shows that oral cancer patients having a lesser number of circulating tumour cells (CTCs) in blood live longer.

Oral cancer patients with less circulating tumour cells live longer than those with more: Study(Pexels)
Oral cancer patients with less circulating tumour cells live longer than those with more: Study(Pexels)
PTI | | Posted by Krishna Priya Pallavi, Pune

A study conducted by a team of Indian researchers has found that oral cancer patients having a lesser number of circulating tumour cells (CTCs) in blood live longer than patients with a greater number of such cells.

The four-year-long study, among the largest clinical trials in head and neck cancers in which 500 patients were analysed, was led by Dr Pankaj Chaturvedi of Tata Memorial Hospital, Mumbai, Dr Jayant Khandare and a team of Pune-based Actorius OncoDiscover Technology.

“Altogether 152 oral cancer patients were analysed and 1.5 ml blood per patient was monitored for the presence of CTCs,” Khandare told PTI. 

ALSO READ | World Cancer Day: Warning signs of common cancers everyone should know about

“The study showed that patients with over 20 CTCs per 1.5 ml blood are more likely to have an advanced-stage disease and nodal metastasis (cancer cells breaking away from where they first formed), while patients with less than 12 CTCs per 1.5 ml blood survive for a longer period,” he said. 

“The study was published in the international peer-reviewed Journal Triple OOO recently,” he added. 

“As per the national cancer registry, there are about 14 lakh cancer patients in India and about nine per cent of these (1.2 lakh) are in Maharashtra,” Khandare said. 

ALSO READ | E-cigarettes no better than regular ones. Study finds they can harm your liver

“Cancer cases and deaths in Maharashtra have increased by 11,306 and 5,727, respectively in last three years, a collective increase of around eight per cent,” he added. 

“The OncoDiscover test, funded by the government through Biotech Ignition Grant and Small Business Industry Research Initiative of the Department of Biotechnology, is the sole CTC test approved by Drugs Controller General of India as per the Medical Device Rules 2017,” he said. 

“The test is used to detect CTCs for diagnosis of cancers like those of head and neck, breast, lung, colon and rectal,” Khandare said. “Maharashtra Health Minister Rajesh Tope has evinced an interest in our work and will be visiting our Pune facility soon," he added. 

This story has been published from a wire agency feed without modifications to the text.
SHARE THIS ARTICLE ON
Topics
SHARE
Story Saved
×
Saved Articles
Following
My Reads
My Offers
Sign out
New Delhi 0C
Friday, December 02, 2022
Start 15 Days Free Trial Subscribe Now
Register Free and get Exciting Deals